Pharmaceutical giant GlaxoSmithKline has responded to pressure from socially responsible investment managers and reduced the costs of essential medicines and drugs for developing countries.
GSK will start offering all under developed countries – particularly the sub-Saharan African countries where the need is rife – “preferential prices” for HIV/AIDS and anti-malarial drugs. Hender...
To continue reading this article...
Join Professional Pensions
- Unlimited access to real-time news, analysis and opinion from the industry
- Receive our in-depth monthly magazine in either print or digital format
- Access our Sustainable Investment Hub covering news and opinion from thought leaders in the ESG space
- Receive important and breaking news stories selected by the Editors in our daily newsletter
- Hear from industry experts and other forward-thinking leaders
- Receive a monthly members-only newsletter with exclusive opinion pieces from leading industry experts and a feature from the magazine in advance of its release date